FOLH1 and prostate cancer: In addition to using PSMA PET for the diagnosis of prostate cancer, PSMA-targeting radioligand therapies (RLTs) have been developed and have shown benefit in the metastatic, castrate-resistant prostate cancer (CRPC) setting.